Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*

Derek C. Angus; Walter T. Linde‐Zwirble; Gilles Clermont; Daniel Ball; Bruce R. Basson; E. Wesley Ely; Pierre‐François Laterre; Jean Louis Vincent; Gordon R. Bernard; Ben van Hout

doi:10.1097/00003246-200301000-00001

Back

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*

Article 2003 en

Authors

DA
Derek C. Angus
WL
Walter T. Linde‐Zwirble
GC
Gilles Clermont

Abstract

1 min read

Drotrecogin alfa has a cost-effectiveness profile similar to that of many well-accepted healthcare strategies and below commonly quoted thresholds.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2006

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

E. Wesley Ely, Pierre‐François Laterre, Derek C. Angus, Jeffrey D. Helterbrand, Howard Levy, Jean-François Dhainaut, Jean Louis Vincent, William L. Macias, Gordon R. Bernard

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*

Abstract

Discussion(0)

Related publications

Drotrecogin alfa (activated) in the treatment of severe sepsis

Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis

Drotrecogin alfa: a new approach in the treatment of severe sepsis

Drotrecogin alfa (activated): the treatment for severe sepsis?

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis